CBL-514 is being called a fat-dissolving shot, but it is not a fat burner, a supplement, or a GLP-1. It is an investigational small-molecule injection from Caliway Biopharmaceuticals, designed to trigger fat-cell apoptosis in the area where it is injected. In a 2025 Phase 2 trial, abdominal fat volume dropped versus placebo, with a mean difference of about −216 mL at 8 weeks. Mean body weight in the CBL-514 group was essentially unchanged (+0.02 kg), so this is local fat reduction, not systemic fat burning. High dropout, single-blind design, and sponsor involvement mean the results need cautious reading.
This page is available in